NASDAQ:ACRV

Acrivon Therapeutics (ACRV) Stock Forecast, Price & News

$12.12

-0.43 (-3.43%)

(As of 09:35 AM ET)

Compare

Today's Range: $12.12
▼
$12.86
50-Day Range: $8.38
▼
$14.09
52-Week Range: $8.06
▼
$25.47

Volume: 2,334 shs
Average Volume: 55,945 shs
Market Capitalization: $265.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.60

Acrivon Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 86.5% Upside
$22.60 Price Target
Short Interest: Bearish
2.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.76) to ($3.43) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

816th out of 1,009 stocks

Pharmaceutical Preparations Industry

410th out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Acrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.60, Acrivon Therapeutics has a forecasted upside of 86.5% from its current price of $12.12.
Amount of Analyst Coverage
Acrivon Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.83% of the float of Acrivon Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Acrivon Therapeutics has a short interest ratio ("days to cover") of 5.4.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Acrivon Therapeutics does not currently pay a dividend.
Dividend Growth
Acrivon Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACRV.

2.7

News and Social Media Coverage

News Sentiment
Acrivon Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Acrivon Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for ACRV on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
3 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
63.82% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.76) to ($3.43) per share.
Price to Book Value per Share Ratio
Acrivon Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Acrivon Therapeutics (NASDAQ:ACRV) Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients predicted to benefit from its drug candidates. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is being advanced in a potentially registrational Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Stock News Headlines

May 25, 2023 | americanbankingnews.com

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.60 Average PT from Brokerages

May 12, 2023 | americanbankingnews.com

Acrivon Therapeutics, Inc.'s (NASDAQ:ACRV) Lock-Up Period Set To End on May 15th

May 30, 2023 | Edge On The Street (Ad)

Is Graphite the New Lithium?

Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.

May 10, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Acrivon Therapeutics, Inc. (ACRV)

May 9, 2023 | finance.yahoo.com

Q1 2023 Akoya Biosciences Inc Earnings Call

May 9, 2023 | finanznachrichten.de

Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023 | finance.yahoo.com

Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer

May 9, 2023 | finance.yahoo.com

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 30, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 9, 2023 | americanbankingnews.com

Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at BMO Capital Markets

May 9, 2023 | markets.businessinsider.com

Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from BMO Capital

May 7, 2023 | finance.yahoo.com

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

May 3, 2023 | msn.com

HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation

May 2, 2023 | americanbankingnews.com

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.00 Average PT from Analysts

April 30, 2023 | americanbankingnews.com

Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at LADENBURG THALM/SH SH

April 25, 2023 | finance.yahoo.com

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

April 25, 2023 | americanbankingnews.com

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) to Post Q1 2023 Earnings of ($0.42) Per Share, HC Wainwright Forecasts

April 24, 2023 | finance.yahoo.com

Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023

April 23, 2023 | americanbankingnews.com

HC Wainwright Begins Coverage on Acrivon Therapeutics (NASDAQ:ACRV)

April 20, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy Recommendation

April 18, 2023 | finance.yahoo.com

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

March 28, 2023 | finanznachrichten.de

Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 28, 2023 | finance.yahoo.com

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 28, 2023 | finance.yahoo.com

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 20, 2023 | msn.com

Acrivon Therapeutics stock plunges nearly 30%

March 6, 2023 | finance.yahoo.com

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 1, 2023 | barrons.com

Acrivon Therapeutics Inc.

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Company Calendar

Last Earnings: 3/28/2023
Today: 5/30/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACRV
CUSIP: N/A
CIK: 1781174
Web: www.acrivon.com
Phone: 617-207-8979
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.60
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $17.00
Forecasted Upside/Downside: +80.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.82
Quick Ratio: 21.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.16 per share
Price / Book: 1.54

Miscellaneous

Outstanding Shares: 21,930,000
Free Float: N/A
Market Cap: $275.22 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Peter Blume-Jensen M.D. (Age 61)
Ph.D., Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer
Comp: $645k

Ms. Kristina Masson Ph.D. (Age 43)
Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director

Dr. Eric J. Devroe Ph.D. (Age 45)
Chief Operating Officer
Comp: $375k

Mr. Erick Gamelin M.D. (Age 66)
Ph.D., Chief Medical Officer
Comp: $480.72k

Mr. Rasmus Holm-Jorgensen (Age 52)
Chief Financial Officer

Ms. Katharine Peterson CPA
VP of Fin. & Accounting

Mr. Bruce Close
VP of Quality & Compliance

Ms. Mary-Alice Miller J.D. (Age 49)
Gen. Counsel

Ms. Crystal Mercado
Global Head of HR

Dr. Jesper V. Olsen Ph.D.
Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACRV Stock - Frequently Asked Questions

Should I buy or sell Acrivon Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRV shares.
View ACRV analyst ratings or view top-rated stocks.
What is Acrivon Therapeutics' stock price forecast for 2023?: 7 equities research analysts have issued 12 month target prices for Acrivon Therapeutics' shares. Their ACRV share price forecasts range from $17.00 to $25.00. On average, they predict the company's share price to reach $22.60 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price.
View analysts price targets for ACRV or view top-rated stocks among Wall Street analysts.
How have ACRV shares performed in 2023?: Acrivon Therapeutics' stock was trading at $11.52 at the beginning of 2023. Since then, ACRV shares have increased by 8.9% and is now trading at $12.55.
View the best growth stocks for 2023 here.
When is Acrivon Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ACRV earnings forecast.
How were Acrivon Therapeutics' earnings last quarter?: Acrivon Therapeutics, Inc. (NASDAQ:ACRV) posted its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.30.
When did Acrivon Therapeutics IPO?: (ACRV) raised $100 million in an initial public offering on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

What is Acrivon Therapeutics' stock symbol?: Acrivon Therapeutics trades on the NASDAQ under the ticker symbol "ACRV."
When did the company's lock-up period expire?: Acrivon Therapeutics' lock-up period expired on Monday, May 15th. Acrivon Therapeutics had issued 7,550,000 shares in its initial public offering on November 15th. The total size of the offering was $94,375,000 based on an initial share price of $12.50. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who are Acrivon Therapeutics' major shareholders?: Acrivon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (4.05%), Federated Hermes Inc. (2.80%), BlackRock Inc. (2.16%), Geode Capital Management LLC (0.80%), State Street Corp (0.39%) and Charles Schwab Investment Management Inc. (0.27%). Insiders that own company stock include Ltd Chione and Ra Capital Management, LP.
View institutional ownership trends.
How do I buy shares of Acrivon Therapeutics?: Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acrivon Therapeutics' stock price today?: One share of ACRV stock can currently be purchased for approximately $12.55.
How much money does Acrivon Therapeutics make?: Acrivon Therapeutics (NASDAQ:ACRV) has a market capitalization of $275.22 million.
How can I contact Acrivon Therapeutics?: The official website for the company is www.acrivon.com. The company can be reached via phone at 617-207-8979 or via email at asantos@wheelhouselsa.com.

This page (NASDAQ:ACRV) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Acrivon Therapeutics (ACRV) Stock Forecast, Price & News

Acrivon Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Acrivon Therapeutics (NASDAQ:ACRV) Stock

ACRV Stock News Headlines

ACRV Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACRV Stock - Frequently Asked Questions

Overall MarketRank^™